General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
BORTEZOMIB
BORTEZOMIB
Standard Dose
3.5MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 218688 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 3.5MG/VIAL Sponsor VILIN BIO MED Submission history Latest submission status date: 2025-06-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview BORTEZOMIB is listed in Drugs@FDA under application 218688 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BORTEZOMIB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 3.5MG/VIAL Sponsor VILIN BIO MED Submission history Latest submission status date: 2025-06-02 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.